Diversification of pharmaceutical manufacturing processes: Taking the plunge into the non-PGM catalyst pool

22 March 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Recent global events have led to the cost of platinum group metals (PGMs) reaching unprecedented heights. Many chemical companies are therefore starting to seriously consider and evaluate if, and where, they can substitute PGMs for non-PGMs in their catalytic processes. This review covers recent large-scale applications of non-PGM catalysts in the modern pharmaceutical industry. By highlighting these selected successful examples of non-PGM-catalyzed processes from the literature, we hope to emphasize the enormous potential of non-PGM catalysis and inspire further development within this field to enable this technology to progress towards manufacturing processes. We also present some historical context and review the perceived advantages and challenges of implementing non-PGM catalysts in the pharmaceutical manufacturing environment.

Keywords

non-PGM catalysis
pharmaceutical industry

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.